Mallinckrodt completes $425 million deal
Mallinckrodt has closed on its acquisition of specialty pharmaceutical firm InfaCare Pharmaceutical Corp.
The deal, which was announced in August, could be worth as much as $425 million.
Trevose, Pennsylvania-based InfaCare is focused on developing treatments for neonatal and pediatric patients. The company currently is developing a therapy, known as stannsoporfin, to treat newborns at risk of develo ping jaundice.
"The addition of stannsoporfin further expands and diversifies Mallinckrodt's pediatric…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Angela Mueller Source Type: news
More News: Biotechnology | Health Management | Jaundice | Mergers and Aquisitions | Pediatrics | Perinatology & Neonatology